SCHEMBL2800914

SCHEMBL2800914

CS(=O)(=O)NC(=O)c1cnn2c(NCc3ccccc3)c(C(=O)N3CCC(c4ccccc4F)CC3)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 1/20 0.41
SCN7A Q01118 5/20 0.41
CHRM4 P08173 1/20 0.39
TRPA1 O75762 2/20 0.39
SCN5A Q14524 3/20 0.38
ALDH1A1 P00352 3/20 0.38
AXL P30530 1/20 0.37
FLT3 P36888 1/20 0.37
TYRO3 Q06418 1/20 0.37
MERTK Q12866 1/20 0.37
SCN9A Q15858 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPK14 Q16539 1/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
THRB P10828 2/20 0.36
HCRTR2 O43614 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801027 0.92 RBP4 (0.40) RBP4SCN7AALDH1A1AXLFLT3
SCHEMBL2800901 0.90 CHRM4 (0.43) RBP4CHRM4TRPA1SCN5AALDH1A1
SCHEMBL2799687 0.90 STAT6 (0.40) RBP4ALDH1A1AXLFLT3TYRO3
SCHEMBL2800606 0.89 NPSR1 (0.49) RBP4SCN7ACHRM4ALDH1A1CYP2C9
SCHEMBL2802693 0.89 TP53 (0.41) RBP4SCN7ACHRM4ALDH1A1EGLN1
SCHEMBL2798553 0.88 THRB (0.37) RBP4SCN7AALDH1A1AXLFLT3
SCHEMBL2802391 0.87 SMN1; SMN2 (0.41) ALDH1A1AXLFLT3TYRO3MERTK
SCHEMBL2801428 0.86 ALDH1A1 (0.39) RBP4SCN7AALDH1A1AXLFLT3
SCHEMBL2800864 0.86 CCR1 (0.42) CHRM4TP53THRB
SCHEMBL2800890 0.86 NTRK1 (0.40) SCN7ACHRM4ALDH1A1SCN9AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 RBP4 92/4885SCN7A 168/4885CHRM4 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.